Compare Agora Inc (API) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Agora Inc vs Gilead Sciences, Inc. — how do they compare? Agora Inc trades at $4.2 (market cap $355.95M), while Gilead Sciences, Inc. trades at $130.62 (market cap $161.19B). The key difference: Gilead Sciences, Inc. is far larger — about 452.8× Agora Inc's market cap, and Gilead Sciences, Inc. pays a 2.53% dividend while Agora Inc pays none. Which is the better fit depends on your goals.
| API | GILD | |
|---|---|---|
Market Cap | $355.95M | $161.19B |
Sector | Technology | Health |
52-Week High | $5.26 | $155.80 |
52-Week Low | $3.24 | $108.22 |
Enterprise Value | $108.94M | $175.72B |
Dividend Yield | — | 2.53% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Agora, Inc. (API) trades at $4.22, down 2.54% today, with a bullish technical signal from moving averages and neutral oscillators. The company reported Q1 2026 revenue above guidance and its sixth consecutive quarter of GAAP profitability, with net income of $9.53 million in 2025. Recent news highlights management share purchases and a partnership with thymia for real-time health intelligence.
Outlook remains positive with analyst consensus at 60% buy ratings, supported by strong cash flow growth and a low P/B of 0.64. Key risks include competitive pressures in conversational AI and potential volatility from high short interest growth of 30.3% as of March 31, 2026 (Defense World).
Gilead Sciences (GILD) trades at $129.83, down 3.72% on the day, with a bullish technical signal and strong fundamentals including a 30.99% net income margin and 43.19% ROE. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer expand its oncology portfolio, while earnings have consistently beaten estimates in recent quarters. The stock shows robust profitability and cash flow generation despite a net cash outflow in 2025.
Outlook remains positive with a consensus price target of $154.57 (19% upside), supported by analyst bullishness (67% buy ratings) and growth catalysts in HIV and oncology. Key risks include patent expirations for key drugs and competitive pressures in the biotech sector. The valuation at 17.66x P/E appears reasonable given earnings growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Agora Inc
Agora Inc provides real-time communication solutions. The company offers real-time video calling, voice calling, live audio and video streaming, recording, and real-time messaging. It serves the gaming, retail, and education industries. The company operates in the People's Republic of China and the United States of America and the majority of its revenue is derived from the People's Republic of China.
Read more on API →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
